Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) [Yahoo! Finance]
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.